Last updated: October 26, 2026
Humulin R U-100 is Lilly’s recombinant human regular insulin, marketed as a 100-units-per-milliliter injectable product. It is an established, low-growth insulin franchise with limited patent protection, heavy price competition, and declining strategic importance within Lilly’s diabetes portfolio. Product-specific revenue is not publicly disclosed. Lilly’s financial growth is concentrated in newer incretin products, while Humulin R U-100 remains commercially relevant because of its low cost, broad prescribing familiarity, and use in basal-bolus therapy, insulin pumps, inpatient care, and diabetes treatment where rapid-acting analogs are less affordable.
What is Humulin R U-100 and how is it used?
Humulin R U-100 contains biosynthetic human insulin produced through recombinant DNA technology. It is a short-acting insulin used to improve glycemic control in patients with diabetes mellitus. The product is generally administered approximately 30 minutes before meals, unlike rapid-acting analogs such as insulin lispro, insulin aspart, and insulin glulisine, which are usually administered closer to mealtime. [1]
Humulin R U-100 is distinct from:
- Humulin R U-500, a concentrated 500-units-per-milliliter insulin for patients requiring very high daily doses.
- Humalog, Lilly’s insulin lispro product.
- Lyumjev, Lilly’s ultra-rapid insulin lispro formulation.
- Insulin glargine products, including Lantus and Basaglar.
- Inhaled insulin products such as Afrezza.
The U-100 formulation is sold in vial and prefilled-pen presentations, subject to market availability and local labeling. The product is used in outpatient diabetes care and may be used intravenously in hospital settings under medical supervision. [1]
What is the FDA regulatory status of Humulin R U-100?
Humulin R was approved by the FDA in 1982 and was among the first commercial recombinant human insulin products. Its approval predates the modern 351(k) biosimilar pathway by decades. The product is regulated as a biologic insulin product, but its market competition is shaped by insulin-specific FDA rules rather than by the same commercial dynamics as complex monoclonal antibodies.
The FDA transitioned insulin products approved under the Federal Food, Drug, and Cosmetic Act to regulation under the Public Health Service Act on March 23, 2020. The transition made insulin products eligible for biosimilar and interchangeable biosimilar competition under the 351(k) pathway. [2]
The regulatory consequences are important:
| Issue |
Humulin R U-100 position |
| Original FDA approval |
1982 |
| Active ingredient |
Recombinant human insulin |
| Product type |
Short-acting human insulin |
| FDA biologic transition |
March 23, 2020 |
| Primary competition |
Human insulin, rapid-acting analogs, authorized generics, biosimilar and interchangeable insulin products |
| Product-specific FDA exclusivity |
Expired |
| Current regulatory barrier |
Manufacturing, quality, supply, labeling, and market access requirements |
Humulin R does not have the regulatory exclusivity profile of a recently approved biologic. Its commercial position depends on production economics, payer coverage, pharmacy distribution, brand recognition, and supply reliability.
What patents protect Humulin R U-100?
Humulin R U-100 has no material remaining patent barrier protecting its core active ingredient or original commercial concept. The underlying recombinant human insulin technology and early product patents expired long ago.
The product’s practical protection is therefore not based on a current composition-of-matter patent. Potential intellectual-property rights may still relate to specific manufacturing processes, delivery devices, packaging, cartridge systems, or later presentation changes, but those rights do not create a meaningful barrier to competition against standard human insulin.
Are Humulin R U-100 patents listed in the Orange Book?
Humulin R has historically been associated with FDA drug-listing and approval records, but the commercial significance of Orange Book listings is limited because the core product has been marketed for more than four decades and its foundational exclusivity has expired. Insulin’s 2020 transition to the biologics framework also reduces the usefulness of relying solely on conventional small-molecule Orange Book analysis. [2,3]
The key patent conclusion is:
- No known active composition-of-matter patent protects recombinant human regular insulin as marketed in Humulin R U-100.
- No current patent term should materially delay a competing human-insulin or interchangeable-insulin product.
- Device or formulation patents, if applicable to a particular presentation, would not necessarily block vial-based competition.
- Manufacturing know-how and regulatory comparability remain more important than patent exclusion.
When did Humulin R U-100 lose exclusivity?
Humulin R lost meaningful exclusivity many years ago. The product’s original regulatory and technology protections expired before the current insulin market developed around rebates, preferred formulary placement, and patient affordability programs.
Unlike newer biologics, Humulin R does not have a current reference-product exclusivity period that would delay biosimilar approval. The main commercial question is not when exclusivity ends. It is whether a competitor can manufacture human insulin at scale and obtain favorable payer and pharmacy access.
How many competitors challenge Humulin R U-100?
Humulin R competes across several categories rather than against one direct substitute.
| Competitor category |
Examples |
Competitive effect |
| Branded human regular insulin |
Novolin R from Novo Nordisk |
Direct substitution |
| Authorized or private-label human insulin |
ReliOn-branded human insulin and other channel products |
Strong price pressure |
| Rapid-acting insulin analogs |
Humalog, NovoLog, Apidra, Lyumjev, Fiasp |
Clinical and convenience substitution |
| Concentrated insulin |
Humulin R U-500, U-200 or U-300 analogs |
Captures high-dose or specialized patients |
| Biosimilar or interchangeable insulin |
Products approved under the 351(k) pathway |
Expands substitution options |
| Hospital insulin suppliers |
Multiple manufacturers and contract channels |
Drives procurement-based pricing |
The most direct branded competitor is Novolin R. Rapid-acting analogs are not identical substitutes, but they compete for the same mealtime insulin budget. They offer faster onset and greater dosing convenience, while Humulin R generally retains a cost advantage.
What formulation patents protect Humulin R U-100?
The main Humulin R U-100 formulation is a conventional human insulin injection, not a long-acting or inhaled delivery system. Its market identity comes from the active ingredient, strength, route of administration, and established labeling.
Potentially relevant technical protections in insulin markets include:
- Stabilizers and preservatives.
- Zinc and formulation conditions.
- Injection-device compatibility.
- Pen-cartridge design.
- Container-closure systems.
- Manufacturing and purification processes.
- Storage and cold-chain controls.
These features may support product quality and lifecycle management, but they do not appear to create a strong exclusionary position around standard U-100 regular insulin. The product’s manufacturing process is more important operationally than as a litigation tool.
What is the market outlook for Humulin R U-100?
Humulin R U-100 is a mature product with a stable-to-declining demand profile in developed markets.
The principal market pressures are:
- Shift to insulin analogs. Rapid-acting analogs provide more flexible mealtime dosing and have displaced some regular human insulin use.
- Payer pressure. Insulin reimbursement increasingly favors net price, formulary status, rebates, and affordability programs.
- Retail substitution. Lower-cost private-label and authorized-generic channels reduce brand pricing power.
- Type 2 diabetes treatment changes. GLP-1 receptor agonists and dual GIP/GLP-1 products reduce insulin initiation or delay intensification for some patients.
- Hospital and institutional demand. Regular insulin remains clinically useful in inpatient protocols and intravenous applications.
- Global access demand. Human insulin remains important in lower-income and price-sensitive markets where analogs are less affordable.
The product’s volume base is supported by the large global diabetes population, but unit growth is constrained by substitution and treatment innovation. Its economic profile is closer to a durable genericized biologic than to a growth-stage branded medicine.
What is Lilly’s financial exposure to Humulin R U-100?
Lilly does not publicly report Humulin R U-100 as a standalone revenue line in its annual reports. The company reports revenue by product and therapeutic category, but mature insulin products are not consistently separated at the level required to calculate Humulin R U-100 sales.
Lilly’s recent financial trajectory has been driven by newer diabetes and obesity products:
| Financial driver |
Effect on Humulin R U-100 |
| Mounjaro and Zepbound growth |
Reduces strategic attention on mature insulin |
| Trulicity decline |
Creates portfolio transition pressure |
| Humalog and other insulin products |
Remain established but face pricing pressure |
| Manufacturing scale |
Supports continued supply and lower unit costs |
| Rebate and formulary competition |
Compresses net price |
| Global demand |
Provides volume support outside high-income markets |
Lilly reported total revenue of approximately $34.1 billion in 2023 and approximately $45.0 billion in 2024, reflecting rapid growth from Mounjaro, Zepbound, and other newer products. Humulin R U-100 is not identified as a major standalone growth contributor in those disclosures. [4,5]
For valuation purposes, Humulin R U-100 should be modeled as part of Lilly’s mature insulin base rather than as a separate growth asset. The product likely contributes recurring cash flow, but its incremental revenue growth and pricing power are limited.
What generic entry risks exist for Humulin R U-100?
Generic and biosimilar entry risk is high from a legal perspective because the product has no meaningful core patent barrier. Commercial entry remains more difficult than legal entry because insulin manufacturing is technically demanding and market access is concentrated.
A competitor must establish:
- Consistent recombinant insulin production.
- High-purity active pharmaceutical ingredient.
- Reliable potency and stability.
- Validated aseptic filling.
- Cold-chain distribution.
- FDA-compliant manufacturing controls.
- Payer and pharmacy-channel access.
- Adequate scale to compete on net price.
This creates a manufacturing barrier, but not a durable exclusivity barrier. Established suppliers with insulin production capacity have an advantage over new entrants. A new competitor without scale may obtain approval yet struggle to secure formulary placement or maintain profitable pricing.
Which companies are challenging the Humulin R U-100 franchise?
The competitive field includes Novo Nordisk, Sanofi, Biocon Biologics, Viatris, and private-label insulin distributors, depending on the specific product and market.
Novo Nordisk is the strongest direct branded competitor through Novolin R and a broad insulin portfolio. Sanofi competes more heavily in basal insulin, while Viatris and Biocon have expanded biosimilar insulin participation through products such as Semglee, an interchangeable insulin glargine product. These products do not directly duplicate regular human insulin, but they compete for insulin budgets and payer preference. [6]
Walmart’s ReliOn insulin channel has also increased price competition in the United States by offering lower-cost human insulin and analog products through retail distribution. The commercial effect is strongest among cash-paying patients and price-sensitive populations.
What patent litigation affects Humulin R U-100?
There is no widely recognized current patent litigation blocking generic or biosimilar entry into the standard Humulin R U-100 market. The product’s age and lack of meaningful core patent protection reduce the litigation value of a direct patent challenge.
Potential disputes would more likely involve:
- Manufacturing processes.
- Pen or cartridge technology.
- Product-specific labeling.
- Trade secrets.
- Supply agreements.
- Contract manufacturing.
- Pricing and rebate practices.
These issues can affect commercial access without creating pharmaceutical patent exclusivity.
How does Humulin R U-100 compare with Novolin R?
| Factor |
Humulin R U-100 |
Novolin R |
| Manufacturer |
Eli Lilly |
Novo Nordisk |
| Active ingredient |
Human regular insulin |
Human regular insulin |
| Strength |
U-100 |
U-100 |
| Onset profile |
Conventional regular insulin |
Conventional regular insulin |
| Primary use |
Mealtime and diabetes control |
Mealtime and diabetes control |
| Patent position |
Mature, expired core protection |
Mature, expired core protection |
| Main advantage |
Brand familiarity and Lilly supply network |
Broad Novo Nordisk insulin portfolio |
| Main risk |
Price erosion and analog substitution |
Price erosion and analog substitution |
The two products are clinically close competitors. Differentiation is driven mainly by coverage, price, supply, device presentation, patient familiarity, and distribution rather than by fundamental pharmacology.
What generic launch scenarios are most likely?
The most likely scenarios are:
Continued branded erosion
Humulin R remains available but loses share gradually to lower-priced channels, Novolin R, and formulary-preferred insulin products.
Retail-led substitution
Cash-paying patients and underinsured patients shift toward private-label or lower-cost human insulin, reducing Lilly’s net realized price.
Limited direct biosimilar disruption
A direct interchangeable version of regular human insulin could create price pressure, but approval alone would not guarantee rapid switching. Pharmacy substitution laws, payer contracts, physician habits, and manufacturing capacity would control uptake.
Clinical substitution by analogs
Some patients move from regular insulin to rapid-acting analogs because of dosing convenience. Others move in the opposite direction when affordability becomes the dominant consideration.
What is the geographic coverage of Humulin R U-100?
Humulin is a globally recognized insulin brand, but product names, presentations, reimbursement, and availability differ by country. The strongest commercial relevance is in markets with established Lilly distribution and a large population using human insulin.
In the United States, the product competes in a highly managed pharmacy market with manufacturer rebates, Medicare and commercial formulary controls, retail discount programs, and substantial patient cost-sharing variation. In emerging markets, the value proposition is more closely tied to affordability and dependable supply.
Global manufacturing and regulatory compliance are central barriers. Insulin production requires specialized facilities, validated processes, and strict quality controls. These requirements limit the number of credible suppliers even when patents no longer restrict entry.
Key Takeaways
- Humulin R U-100 is a mature recombinant human regular insulin product first approved in 1982.
- Its core patent protection and regulatory exclusivity expired long ago.
- There is no meaningful current patent moat around standard U-100 regular insulin.
- Product-specific Humulin R revenue is not separately disclosed by Lilly.
- Lilly’s financial growth is now concentrated in Mounjaro, Zepbound, and other newer products.
- Humulin R remains commercially relevant because of affordability, clinical familiarity, and established supply.
- Novolin R, private-label insulin, rapid-acting analogs, and interchangeable insulin products create sustained competitive pressure.
- Manufacturing scale, quality systems, payer access, and distribution are more important than patent litigation.
- The likely financial trajectory is stable-to-declining revenue, continued price compression, and persistent but limited cash generation.
- Direct generic or biosimilar entry would increase pressure, but market adoption would depend on payer contracts and manufacturing scale.
FAQs
Is Humulin R U-100 a biosimilar?
No. Humulin R U-100 is the original Lilly recombinant human insulin product, not a biosimilar. Products approved later under the 351(k) pathway may compete as biosimilar or interchangeable insulin products.
Is Humulin R U-100 still commercially protected?
No meaningful core patent protection remains. Commercial protection comes from manufacturing scale, brand recognition, supply reliability, distribution, and payer relationships.
Is Humulin R U-100 cheaper than Humalog?
It is often less expensive on a list-price or cash-pay basis, but the actual patient cost depends on insurance coverage, rebates, pharmacy pricing, and available discount programs.
Can Humulin R U-100 be substituted automatically for Novolin R?
The products have the same general active ingredient and pharmacologic class, but automatic substitution depends on jurisdiction, product-specific FDA status, pharmacy law, payer rules, and prescriber instructions.
Does Humulin R U-100 compete with GLP-1 drugs?
Yes. GLP-1 receptor agonists and dual GIP/GLP-1 agonists can delay insulin initiation or reduce insulin requirements for some patients with type 2 diabetes. They do not replace insulin for patients with absolute insulin deficiency or type 1 diabetes.
References
-
U.S. Food and Drug Administration. (2023). Humulin R U-100 prescribing information. Eli Lilly and Company.
-
U.S. Food and Drug Administration. (2020). Transition of insulin products and other biological products from the Federal Food, Drug, and Cosmetic Act to the Public Health Service Act.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
-
Eli Lilly and Company. (2024). 2023 annual report.
-
Eli Lilly and Company. (2025). 2024 annual report.
-
U.S. Food and Drug Administration. (2020). FDA approves first interchangeable biosimilar insulin product to treat diabetes.
